NASDAQ:ATXI

Avenue Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ATXI

*Your capital is at risk

$0.320

+0.0200 (+6.67%)

At Close: Jun 23, 2026

Avenue Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.58. In total, the insiders bought 11.69M and sold 2.01M ATXI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.58
● Buy	11.69M shares
● Sell	2.01M shares
82% Buy Activity Strong Negative Correlation
Sell Signal Low Confidence Jun 22, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 99.58. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 02, 2026 Buy	COMMON STOCK, PAR VALUE $0.0001 A-Award	Fortress Biotech, Inc. 10 Percent Owner	10% Owner	111 209 Value: $76.3K
Mar 31, 2025 Buy	COMMON STOCK, PAR VALUE $0.0001 A-Award	Fortress Biotech, Inc. 10 Percent Owner	10% Owner	33 724 Value: $10.1K
Mar 31, 2025 Buy	COMMON STOCK, PAR VALUE $0.0001 A-Award	Fortress Biotech, Inc. 10 Percent Owner	10% Owner	33 724 Value: $10.1K
Dec 31, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001	Fortress Biotech, Inc. 10 Percent Owner	10% Owner	0 Value: $0
Dec 31, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001	Fortress Biotech, Inc. 10 Percent Owner	10% Owner	0 Value: $0
Dec 02, 2024 Sell	COMMON STOCK, PAR VALUE $0.0001 S-Sale	Herskowitz Neil Director	Director	23 Value: $46
Dec 02, 2024 Sell	COMMON STOCK, PAR VALUE $0.0001 S-Sale	Herskowitz Neil Director	Director	23 Value: $46
Nov 05, 2024 Sell	COMMON STOCK, PAR VALUE $0.0001 S-Sale	Kranzler Jay D Director	Director	61 Value: $137
Nov 05, 2024 Sell	COMMON STOCK, PAR VALUE $0.0001 S-Sale	Kranzler Jay D Director	Director	61 Value: $137
Sep 30, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001 P-Purchase	Kranzler Jay D Director	Director	497 Value: $1K
Sep 30, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001 P-Purchase	Kranzler Jay D Director	Director	497 Value: $1K
Sep 27, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001 P-Purchase	Kranzler Jay D Director	Director	3 Value: $7
Sep 27, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001 P-Purchase	Kranzler Jay D Director	Director	3 Value: $7
Sep 23, 2024 Buy	Employee stock option (right to buy) A-Award	Rosenwald Lindsay A Md Director	Director	30 000 Value: $73.8K
Sep 23, 2024 Buy	Employee stock option (right to buy) A-Award	Herskowitz Neil Director	Director	30 000 Value: $73.8K
Sep 23, 2024 Buy	Employee stock option (right to buy) A-Award	Oltmans Curtis Gale Director	Director	30 000 Value: $73.8K
Sep 23, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001 A-Award	Maclean Alexandra Chief Executive Officer	CEO / President	170 000 Value: $406.3K
Sep 23, 2024 Buy	Employee stock option (right to buy) A-Award	Kranzler Jay D Director	Director	30 000 Value: $73.8K
Sep 23, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001 A-Award	Jin David Interim Pfo And COO	C-Suite Officer	65 000 Value: $155.4K
Sep 23, 2024 Buy	Employee stock option (right to buy) A-Award	Charles Faith L. Director	Director	30 000 Value: $73.8K
Sep 23, 2024 Buy	Employee stock option (right to buy) A-Award	Charles Faith L. Director	Director	30 000 Value: $73.8K
Sep 23, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001 A-Award	Jin David Interim Pfo And COO	C-Suite Officer	65 000 Value: $155.4K
Sep 23, 2024 Buy	Employee stock option (right to buy) A-Award	Kranzler Jay D Director	Director	30 000 Value: $73.8K
Sep 23, 2024 Buy	COMMON STOCK, PAR VALUE $0.0001 A-Award	Maclean Alexandra Chief Executive Officer	CEO / President	170 000 Value: $406.3K
Sep 23, 2024 Buy	Employee stock option (right to buy) A-Award	Oltmans Curtis Gale Director	Director	30 000 Value: $73.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AVENUE THERAPEUTICS, INC.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York....

Read Full Profile Here